FIGURE 1.

Selection and characterization of CXCR7-specific Nanobodies. A, ¹²⁵I-CXCL12 displacement screening of purified monoclonal Nanobodies (10⁻⁶ m) on hCXCR7-expressing NIH-3T3 cells. Unlabeled human CXCL12 and a CXCR7-unrelated Nanobody were used as controls to determine the specificity of the radioligand and control for non-specific effects of Nanobodies. B, ¹²⁵I-CXCL12 displacement assay on stable hCXCR7-expressing NIH-3T3 cells with cold CXCL12, CXCR7-specific Nanobodies (NB), monoclonal antibody (mAb) 8F11, and small non-peptidergic compound VUF11403. C, ¹²⁵I-CXCL12 radioligand binding assay on membrane extracts from HEK293T cells transiently transfected with hCXCR4.